Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.30 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10065471 | 0.88 | CDC25B (0.37) | CDC25BSLC22A12KDM4EALDH1A1HPGD | |
| SCHEMBL19565778 | 0.79 | CDC25B (0.31) | CDC25BCYP3A4ALOX15HSD17B10 | |
| SCHEMBL4071878 | 0.74 | CDC25B (0.47) | CDC25BCYP1A2CYP3A4ALOX15TSHR | |
| SCHEMBL16561504 | 0.73 | — | — | |
| SCHEMBL15219165 | 0.73 | APAF1 (0.30) | — | |
| SCHEMBL18265864 | 0.73 | KDM4E (0.43) | CDC25BCYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL19575376 | 0.73 | KDM4E (0.43) | CDC25BCYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL361673 | 0.71 | KDM4E (0.37) | KDM4ETDP1 | |
| SCHEMBL22435860 | 0.69 | CDC25B (0.43) | CDC25BCYP1A2CYP3A4 | |
| SCHEMBL18867264 | 0.69 | CDC25B (0.43) | CDC25BCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170216291-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2017-08-03 | — | — | US | disclosed |
| US-8916563-B2 | Aldose reductase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-12-23 | — | — | US | disclosed |
| US-20130225592-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216291-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | ALDOA, AKR1B1, AKR1C2 | CDC25B 1875/4885SLC22A12 2449/4885CYP1A2 1039/4885 |
| US-20130225592-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | ALDOA, AKR1B1, AKR1C2 | CDC25B 1875/4885SLC22A12 2449/4885CYP1A2 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.